The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Cognitive Function in a Randomized Trial of Evolocumab
Open accessAbstract
Background Findings from clinical trials of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors have led to concern that these drugs or the low levels of low-density lipoprotein (LDL) cholesterol that result from their use are associated with cognitive deficits. Methods In a subgroup of patients from a randomized, placebo-controlled trial of evolocumab added to statin therapy, we prospectively assessed cognitive function using the Cambridge Neuropsychological Test Automated Battery. The primary end point was the score on the spatial working memory strategy index of executive function (scores range from 4 to 28, with lower scores indicating a more efficient use of strategy and planning). Secondary end points were the scores for working memory (scores range from 0 to 279, with lower scores indicating fewer errors), episodic memory (scores range from 0 to 70, with lower scores indicating fewer errors), and psychomotor speed (scores range from 100 to 5100 msec, with faster times representing better performance). Assessments of cognitive function were performed at baseline, week 24, yearly, and at the end of the trial. The primary analysis was a noninferiority comparison of the mean change from baseline in the score on the spatial working memory strategy index of executive function between the patients who received evolocumab and those who received placebo; the noninferiority margin was set at 20% of the standard deviation of the score in the placebo group. Results A total of 1204 patients were followed for a median of 19 months; the mean (±SD) change from baseline over time in the raw score for the spatial working memory strategy index of executive function (primary end point) was -0.21±2.62 in the evolocumab group and -0.29±2.81 in the placebo group (P<0.001 for noninferiority; P=0.85 for superiority). There were no significant between-group differences in the secondary end points of scores for working memory (change in raw score, -0.52 in the evolocumab group and -0.93 in the placebo group), episodic memory (change in raw score, -1.53 and -1.53, respectively), or psychomotor speed (change in raw score, 5.2 msec and 0.9 msec, respectively). In an exploratory analysis, there were no associations between LDL cholesterol levels and cognitive changes. Conclusions In a randomized trial involving patients who received either evolocumab or placebo in addition to statin therapy, no significant between-group difference in cognitive function was observed over a median of 19 months. (Funded by Amgen; EBBINGHAUS ClinicalTrials.gov number, NCT02207634 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Trials of PCSK9 inhibitors in cardiovascular populations consistently showed substantial reductions in LDL cholesterol without negative cognitive effects [11,22].”
From The Roles of PCSK9 in Alzheimer’s Disease: A Systematic Review of Clinical, Genetic, and Preclinical Evidence (2025) · cites this paper as [22]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“an anti-PCSK9 antibody study observed no significant between-group difference in cognitive function over a median of 19 months [66].”
From PCSK9 acts as a key regulator of Aβ clearance across the blood–brain barrier (2022) · cites this paper as [66]
The cited source says what the claim attributes to it.
In the citing paper
“large cardiovascular trials of PCSK9 antibodies such as evolocumab have not demonstrated cognitive harm10,43”
From Small-molecule PCSK9 inhibition enhances BBB amyloid-β clearance and suppresses microglial inflammation in Alzheimer’s disease models (2026) · cites this paper as [43]
The cited source says what the claim attributes to it.
In the citing paper
“In addition, no change in cognitive function has been reported in studies with the addition of ezetimibe (119) or PCSK9 inhibitors (121,170) to statin therapy, including among individuals treated to very low LDL cholesterol levels.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [170]
The cited source says what the claim attributes to it.
In the citing paper
“In addition, no change in cognitive function has been reported in studies with the addition of ezetimibe (112) or PCSK9 monoclonal antibodies (115,164) to statin therapy, including among individuals treated to very low LDL cholesterol levels.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [164]
The cited source says what the claim attributes to it.
In the citing paper
“Our findings are in line with data from PCSK9 inhibitor clinical trials (Giugliano et al., 2017; Mannarino et al., 2018; Gencer et al., 2020; Ray et al., 2020) and from observations that people carrying loss-of-function mutations of the PCSK9 gene have no signs of neurological defects (Cohen et al., 2005, 2006; Zhao et al., 2006; Hooper et al., 2007; Mefford et al., 2018).”
From PCSK9 deficiency alters brain lipid composition without affecting brain development and function (2023) · cites this paper as Giugliano et al., 2017
In the citing paper
“The absolute benefit from statin treatment was lower in people in primary prevention, who are typically at lower risk [36,38,214,215].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [215]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Self-citationEzetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Self-citationEfficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Self-citationEfficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Sabatine, M. S., Giugliano, R. P., Wiviott, S. D., Raal, F. J., Blom, D. J., Robinson, J., Ballantyne, C. M., Somaratne, R., Legg, J., Wasserman, S. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500858 · Cited by 1,509
Self-citationPlanning and spatial working memory following frontal lobe lesions in man
Owen, A. M., Downes, J. J., Sahakian, B. J., Polkey, C. E., & Robbins, T. W. (1990) · Neuropsychologia · doi:10.1016/0028-3932(90)90137-d · Cited by 1,284
SAHAKIAN, B. J., MORRIS, R. G., EVENDEN, J. L., HEALD, A., LEVY, R., PHILPOT, M., & ROBBINS, T. W. (1988) · Brain · doi:10.1093/brain/111.3.695 · Cited by 666
The measurement of everyday cognition (ECog): Scale development and psychometric properties.
Farias, S. T., Mungas, D., Reed, B., Cahn, D. A., Jagust, W. J., Baynes, K., & DeCarli, C. S. (2008) · Neuropsychology · doi:10.1037/0894-4105.22.4.531 · Cited by 665
Robbins, T. W., James-Galton, M., Owen, A. M., Sahakian, B. J., Lawrence, A. D., McInnes, L., & Rabbitt, P. (1998) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617798455073 · Cited by 629
Schmermund, A., Möhlenkamp, S., Stang, A., Grönemeyer, D. H. W., Seibel, R. M. M., Hirche, H., Mann, K., Siffert, W., Lauterbach, K. W., Siegrist, J., et al. (2002) · American Heart Journal · doi:10.1067/mhj.2002.123579 · Cited by 582
Flagged first, then by citations
Research works printed but not linked: 1
- Jessup C. Cambridge Cognition awarded FDA marketing clearance for Cantab mobile. FDA News. January 26, 2017 (http://www.fdanews.com/articles/180219-cambridge-cognition-awarded-fda-marketing-clearance-for-cantab-mobile).
Cited by
Sorted by citations
Items 201–300 of 493
Feinkohl, I., Winterer, G., & Pischon, T. (2018) · Journal of Epidemiology & Community Health · doi:10.1136/jech-2017-210338 · Cited by 16
Sperlongano, S., Gragnano, F., Natale, F., D’Erasmo, L., Concilio, C., Cesaro, A., Golia, E., Crisci, M., Sperlongano, R., Fimiani, F., et al. (2018) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000620 · Cited by 16
CVD Risk Stratification in the PCSK9 Era: Is There a Role for LDL Subfractions?
Kjellmo, C. A., Hovland, A., & Lappegård, K. T. (2018) · Diseases · doi:10.3390/diseases6020045 · Cited by 16
LDL-Cholesterol-Lowering Therapy
Pirillo, A., Norata, G. D., & Catapano, A. L. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_361 · Cited by 17
Cognition, Statins, and Cholesterol in Elderly Ischemic Stroke Patients: A Neurologist’s Perspective
Jurcău, A., & Simion, A. (2021) · Medicina · doi:10.3390/medicina57060616 · Cited by 16
Girolamo, F. G. D., Pellin, L., Roni, C., Biolo, G., Sinagra, G., & Fabris, E. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.106442 · Cited by 16
Pinto, R. D., Grassi, D., Properzi, G., Desideri, G., & Ferri, C. (2019) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-019-00323-7 · Cited by 16
PCSK9 monoclonal antibodies: An overview
Kaddoura, R., Orabi, B., & Salam, A. M. (2020) · Heart Views · doi:10.4103/heartviews.heartviews_20_20 · Cited by 17
Patel, P. N., & Giugliano, R. P. (2020) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2020.39 · Cited by 19
Self-citationLong-Term Lipid Lowering With Evolocumab in Older Individuals
Said, S. A., O’Donoghue, M. L., Ran, X., Murphy, S. A., Atar, D., KEECH, A. C., Flores‐Arredondo, J. H., Wang, B., Sabatine, M. S., & Giugliano, R. P. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.11.019 · Cited by 15
Self-citationAn updated review of lipid‐modifying therapy
Simons, L. A. (2019) · The Medical Journal of Australia · doi:10.5694/mja2.50142 · Cited by 18
Quiroga, B., Ramos, P. M., & Chiva, V. Á. (2020) · Nefrología · doi:10.1016/j.nefro.2020.04.020 · Cited by 16
An update on PCSK9 inhibitors- pharmacokinetics, drug interactions, and toxicity
Moșteoru, S., Gaiță, D. I., & Banach, M. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1828343 · Cited by 15
Managing dyslipidemia for CVD prevention
Ciffone, N. A., & COPPLE, T. M. (2018) · The Nurse Practitioner · doi:10.1097/01.npr.0000550246.96902.de · Cited by 15
Pharmacokinetics of current and emerging treatments for hypercholesterolemia
Tomlinson, B., Chan, P., Zhang, Y., Liu, Z., & Lam, C. W. K. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1749261 · Cited by 16
Cho, K. H., & Hong, Y. J. (2020) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2020.140 · Cited by 16
Role of PCSK9 inhibitors in the management of dyslipidaemia
Nair, T. (2024) · Indian Heart Journal · doi:10.1016/j.ihj.2023.12.011 · Cited by 16
Khorsandi, M., Blumenthal, R. S., Blaha, M. J., & Kohli, P. (2024) · Clinical Cardiology · doi:10.1002/clc.24284 · Cited by 14
Sheth, S., Banach, M., & Toth, P. P. (2024) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2024.2398444 · Cited by 14
Lipid Target in Very High-Risk Cardiovascular Patients: Lesson from PCSK9 Monoclonal Antibodies
Ciccarelli, G., D’Elia, S., Paulis, M. D., Golino, P., & Cimmino, G. (2018) · Diseases · doi:10.3390/diseases6010022 · Cited by 14
PCSK9 genetic variants and cognitive abilities: a large-scale Mendelian randomization study
Lyall, D. M., Ward, J., Banach, M., Smith, G. D., Gill, J. M. R., Pell, J. P., Holmes, M. V., & Sattar, N. A. (2021) · Archives of Medical Science · doi:10.5114/aoms/127226 · Cited by 15
Ponte-Negretti, C. I., Wyss, F., Piskorz, D. L., Santos, R. D., Villar, R., Lorenzatti, A., López-Jaramillo, P. A., Toth, P. P., Amaro, A. J. J., Rodrigo, A. K., et al. (2021) · Archivos de cardiología de México · doi:10.24875/acm.21000005 · Cited by 21
Gaine, S. P., Quispe, R., Patel, J., & Michos, E. D. (2022) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-022-00694-y · Cited by 14
Evolocumab: Considerations for the Management of Hyperlipidemia
Wiggins, B. S., Senfield, J., Kassahun, H., Lira, A., & Somaratne, R. M. (2018) · Current Atherosclerosis Reports · doi:10.1007/s11883-018-0720-3 · Cited by 14
Alkhalil, M. (2018) · Current Drug Metabolism · doi:10.2174/1389200219666180816141827 · Cited by 14
Statin therapy for young adults: A long-term investment worth considering
Miedema, M. D., Nauffal, V. D., Singh, A., & Blankstein, R. (2019) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.02.004 · Cited by 14
Drug Discovery for Coronary Artery Disease
Wan, Q., Qian, S., Yonghu, H., Zhang, Y., Peng, Z., Li, Q., Shu, B., Zhu, L., & Wang, M. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-2517-9_8 · Cited by 13
Barter, P. J., Yamashita, S., Laufs, U., Ruiz, Á. J., Sy, R. G., Fang, M. D. G., Folco, E., Libby, P., Matsuzawa, Y., & Santos, R. D. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01265-z · Cited by 13
Armario, P., Brotons, C., Elosúa, R., de Leciñana, M. A., Castro, A., Clarà, A. B. I., Cortés, O., Rodríguez, Á. D., Herranz, M., Justo, S., et al. (2020) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2020.07.004 · Cited by 13
Lipid-lowering Drugs and Neurocognitive Function: A Systematic Review
Kyriakos, G., Quiles-Sánchez, L. V., Diamantis, E., Farmaki, P., Garmpis, N., Damaskos, C., Savvanis, S., Patsouras, A., Stelianidi, A., Voutyritsa, E., et al. (2020) · In Vivo · doi:10.21873/invivo.12144 · Cited by 13
PCSK9 Inhibition in Atherosclerotic Cardiovascular Disease
Delialis, D., Dimopoulou, M., Papaioannou, M., Kotsira, G., Maneta, E., Mavraganis, G., Loutos, C., Georgiopoulos, G. A., & Stamatelopoulos, K. S. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230412105238 · Cited by 13
Pleiotropy of PCSK9: Functions in Extrahepatic Tissues
Şener, Y. Z., & Tokgözoğlu, L. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01918-2 · Cited by 13
Seijas‐Amigo, J., Mauriz-Montero, M. J., Suárez‐Artime, P., Gayoso-Rey, M., Estany-Gestal, A., Casas-Martínez, A., González-Freire, L., Rodríguez-Vázquez, A., Pérez-Rodríguez, N. D., Villaverde-Piñeiro, L., et al. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00604-6 · Cited by 13
Current and Emerging Therapeutic Approaches for Vascular Cognitive Impairment and Dementia
Goodall, L., Lennon, M. J., Sachdev, P. S., Gorelick, P. B., Kovacic, J. C., & Samaras, K. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.09.1502 · Cited by 14
Proprotein convertase subtilisin/kexin type 9
Stoekenbroek, R. M., & Kastelein, J. J. P. (2018) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000517 · Cited by 14
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition: The Big Step Forward in Lipid Control
Rikhi, R. R., & Shapiro, M. D. (2023) · European Cardiology Review · doi:10.15420/ecr.2023.14 · Cited by 13
Santos, R. D., Ruzza, A., Wang, B., Maruff, P. T., Schembri, A. J., Bhatia, A. K., Mach, F., Bergeron, J., Gaudet, I., St‐Pierre, J., et al. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad332 · Cited by 12
Self-citationKorthauer, L. E., Giugliano, R. P., Guo, J., Sabatine, M. S., Sever, P., Keech, A., Atar, D., Kurtz, C., Ruff, C. T., Mach, F., et al. (2022) · PLOS ONE · doi:10.1371/journal.pone.0266615 · Cited by 11
Self-citationDiretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose – 2025
Rached, F. H., Miname, M. H., Rocha, V. Z., Zimerman, A., Cesena, F. Y., Sposito, A. C., Santos, R. D., Behr, P. E. B., Bianco, H. T., Alves, R. J., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250640 · Cited by 42
Leiter, L. A., Hegele, R. A., Brown, V., Bergeron, J., Mackinnon, E. S., & Mancini, G. B. J. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2505190 · Cited by 12
Achieving More Optimal Lipid Control with Non-Statin Lipid Lowering Therapy
Nicholls, S. J., & Nelson, A. J. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01280-4 · Cited by 12
Improvement initiative in LDL-C management in Saudi Arabia: A call to action
Alasnag, M. A., Awan, Z. A., Ghamdi, A. A., Modaimeigh, H. A., & Shemiri, M. A. (2020) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2020.100667 · Cited by 11
The Impact of the COVID-19 Outbreak on Patients’ Adherence to PCSK9 Inhibitors Therapy
Caso, V. M., Sperlongano, S., Liccardo, B., Romeo, E., Padula, S., Arenga, F., D’Andrea, A., Caso, P., Golino, P., Nigro, G., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11030475 · Cited by 11
Hermel, M., Lieberman, M., Slipczuk, L. N., Rana, J. S., & Virani, S. S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020459 · Cited by 11
The Link between miRNAs and PCKS9 in Atherosclerosis
Mačvanin, M., Gluvic, Z. M., Klisic, A. N., Manojlovic, M. S., Suri, J. S., Rizzo, M., & Isenović, E. R. (2023) · Current Medicinal Chemistry · doi:10.2174/0109298673262124231102042914 · Cited by 13
PCSK9: from molecular biology to clinical applications
Malo, J., Parajuli, A., & Walker, S. W. (2019) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563219864379 · Cited by 12
Nishikido, T., & Ray, K. K. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14851 · Cited by 11
Thongtang, N., Tangkittikasem, N., Samaithongcharoen, K., Piyapromdee, J., Srinonprasert, V., & Sriussadaporn, S. (2020) · Vascular Health and Risk Management · doi:10.2147/vhrm.s270751 · Cited by 11
PCSK9 inhibitors for prevention of atherosclerotic cardiovascular disease
Bittner, V., Giugliano, R. P., Brinton, E. A., & Guyton, J. R. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.06.013 · Cited by 11
Self-citation2025 AHA/ACC Clinical Performance and Quality Measures for Patients With Chronic Coronary Disease
Williams, M. S., Levine, G. N., Kalra, D. K., Agarwala, A., Baptiste, D., Cigarroa, J. E., Diekemper, R. L., Foster, M., Gulati, M., Henry, T. D., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.02.001 · Cited by 13
Anti-PCSK9 treatment: is ultra-low low-density lipoprotein cholesterol always good?
Noto, D., Giammanco, A., Barbagallo, C. M., Cefalu, A. B., & Averna, M. R. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy144 · Cited by 11
Iluţ, S., Pîrlog, B. O., Pîrlog, R., Nutu, A. M., Văcăraș, V., & Armean, S. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810221 · Cited by 11
Sindi, A. A. A. (2023) · Journal of Lipids · doi:10.1155/2023/2025490 · Cited by 11
Jakobsson, J., Burtin, C., Hedlund, M., Boraxbekk, C., Westman, J., Karalija, N., Stål, P., Sandström, T., Ruttens, D., Gosker, H. R., et al. (2024) · Trials · doi:10.1186/s13063-024-08481-3 · Cited by 11
Tomlinson, B., Chan, P., Zhang, Y., & Lam, C. W. K. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1801638 · Cited by 11
PCSK-9 Inhibitors and Cardiovascular Outcomes: A Systematic Review With Meta-Analysis
Bodapati, A. P., Hanif, A., Okafor, D. K., Katyal, G., Kaur, G., Ashraf, H., & Khan, S. (2023) · Cureus · doi:10.7759/cureus.46605 · Cited by 15
Alirocumab for low-density Lipoprotein Cholesterol Lowering
Roth, E. M. (2018) · Future Cardiology · doi:10.2217/fca-2018-0072 · Cited by 9
Aranzulla, T. C., Piazza, S., Ricotti, A., Musumeci, G., & Gaggiano, A. (2021) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.29743 · Cited by 9
Chakraborty, A., Pang, J., Chan, D. C., Barnett, W., Woodward, A. M., Vorster, M., & Watts, G. F. (2021) · Clinical Cardiology · doi:10.1002/clc.23607 · Cited by 9
Cholesterol Management in Neurology: Time for Revised Strategies?
Andronie-Cioară, F. L., Jurcău, A., Jurcău, M. C., Nistor-Cseppento, C. D., & Simion, A. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12121981 · Cited by 9
The New Face of Hyperlipidemia and the Role of PCSK9 Inhibitors
Nicholls, S. J. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1103-2 · Cited by 10
Brandts, J., & Müller‐Wieland, D. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0802-x · Cited by 9
Biotechnology Approaches for the Treatment of Dyslipidemia
Parolini, C. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07017-6 · Cited by 10
Reddin, C., Stankard, A., Chan, K. Y., Krewer, F., Judge, C., Canavan, M., Davis, D. H. J., & O’Donnell, M. (2025) · Age and Ageing · doi:10.1093/ageing/afaf219 · Cited by 8
Systems genetics of metabolic health in the BXD mouse genetic reference population
Li, X., Morel, J., Masi, A. D., Lalou, A., Sulc, J., Benegiamo, G., Poisson, J., Liu, Y. J., von Alvensleben, G., Maxime, N., et al. (2024) · Cell Systems · doi:10.1016/j.cels.2024.05.006 · Cited by 9
PCSK9 Monoclonal Antibodies Have Come a Long Way
Zendjebil, S., & Steg, P. G. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01243-1 · Cited by 8
Targeting the awry Aβ pathway in Alzheimer’s disease: hype and hurdles
Al-Kuraishy, H. M., Sulaiman, G. M., Al-Gareeb, A. I., Mohammed, H. A., Albuhadily, A. K., & Abomughaid, M. M. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01983-9 · Cited by 8
Yuet, W. C., Ebert, D., & Jann, M. (2021) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098620959271 · Cited by 8
Gavina, C., Seabra, D., Aguíar, C., Anastassopoulou, A., Teixeira, C. A. C., Ruivo, J., Almeida, É., Duarte, L. L., Corte‐Real, A., Canelas‐Pais, M., et al. (2023) · Clinical Cardiology · doi:10.1002/clc.24183 · Cited by 9
Effects of Evolocumab on Cardiovascular Events
Mikhail, N. E. (2017) · Current Cardiology Reviews · doi:10.2174/1573403x13666170918165713 · Cited by 9
Low-Density Lipoprotein Cholesterol After an Acute Coronary Syndrome: How Low to Go?
Qamar, A., & Libby, P. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1160-6 · Cited by 8
Lütjohann, D., Stellaard, F., Bölükbasi, B., Kerksiek, A., Parhofer, K. G., & Laufs, U. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14841 · Cited by 8
The challenge of choosing in cardiovascular risk management
Hoogeveen, R. M., Hanssen, N. M. J., Brouwer, J., Mosterd, A., Tack, C. J., Kroon, A. A., de Borst, G. J., ten Berg, J. M., Trier, T. J. V., van Lennep, J. E. R., et al. (2021) · Netherlands Heart Journal · doi:10.1007/s12471-021-01599-y · Cited by 9
Blood Pressure and Statin Effects on Cognition: a Review
Yang, M., & Williamson, J. D. (2019) · Current Hypertension Reports · doi:10.1007/s11906-019-0973-4 · Cited by 8
PCSK9 Inhibitors: From Nature’s Lessons to Clinical Utility
Raal, F. J., CHILTON, R. J., Ranjith, N., Rambiritch, V., Leisegang, R. F., Ebrahim, I. O., van Tonder, A., Shunmoogam, N., Bouharati, C., Musa, M. G., et al. (2020) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530320666200213114138 · Cited by 8
Schlunk, F., Fischer, P., Princen, H. M. G., Rex, A., Prinz, V., Foddis, M., Lütjohann, D., Laufs, U., & Endres, M. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112875 · Cited by 10
A review on the efficacy and safety of lipid-lowering drugs in neurodegenerative disease
Rajabian, A., McCloskey, A. P., Jamialahmadi, T., Moallem, S. A., & Sahebkar, A. (2023) · Reviews in the Neurosciences · doi:10.1515/revneuro-2023-0005 · Cited by 7
Safety and Efficacy of Achieving Very Low LDL Cholesterol Concentrations with PCSK9 Inhibitors
Balakrishna, A. M., Kaushik, S., Tandalam, S., Monther, N., Ponamgi, S., Alla, V. M., & Patil, S. M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14134562 · Cited by 8
Proprotein convertase subtilisin/kexin Type 9 inhibitors: past, present, and future
Sabatine, M. S., & Laufs, U. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag148 · Cited by 7
Self-citationFrom clinical development to real-world outcomes with inclisiran
Connolly, D. L., Sharma, V., & Ray, K. K. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000954 · Cited by 9
Statin alternatives for the treatment of hypercholesterolemia - a safety evaluation
Zeng, W., & Tomlinson, B. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2424411 · Cited by 7
PCSK9 inhibitor valuation: A science‐based review of the two recent models
Baum, S. J., & Cannon, C. P. (2018) · Clinical Cardiology · doi:10.1002/clc.22924 · Cited by 7
Alirocumab as add-on therapy to statins: current evidence and clinical potential
Auer, J., & Berent, R. (2018) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944718775352 · Cited by 7
Preclinical discovery and development of evolocumab for the treatment of hypercholesterolemia
Khoury, É., Brisson, D., & Gaudet, D. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1704728 · Cited by 6
A stepwise approach to prescribing novel lipid-lowering medications
Kakavand, H., Aghakouchakzadeh, M., Shahi, A., Virani, S. S., Dixon, D. L., Tassell, B. W. V., & Talasaz, A. H. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.10.003 · Cited by 7
Ups and downs in PCSK9 inhibition in the cardiovascular arena: a review
McClintick, D. J., & Giugliano, R. P. (2023) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000897 · Cited by 7
Self-citationAtherosclerosis Residual Lipid Risk-Overview of Existing and Future Pharmacotherapies
Omari, M., & Alkhalil, M. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11040126 · Cited by 9
Recent insights into low-density lipoprotein metabolism and therapy
Pirillo, A., Catapano, A. L., & Norata, G. D. (2020) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000727 · Cited by 7
Vani, A. K., & Underberg, J. A. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1133 · Cited by 7
Robinson, J. G. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.03.040 · Cited by 7
Self-citationWilliams, M. S., Levine, G. N., Kalra, D. K., Agarwala, A., Baptiste, D., Cigarroa, J. E., Diekemper, R. L., Foster, M., Gulati, M., Henry, T. D., et al. (2025) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/hcq.0000000000000140 · Cited by 8
Banach, M., Toth, P. P., Ahn, H., Bielecka-Dabrowa, A. M., Cicero, A. F. G., Covic, A. C., Dalakoti, M., Escobar, C., Fogacci, F., Gaiță, D. I., et al. (2025) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2025.11.003 · Cited by 8
PCSK-9 inhibitors: a new direction for the future treatment of ischemic stroke
Zhou, L., Zhang, H., Wang, S., Zhao, H., Li, Y., Han, J., Zhang, H., Li, X., & Qu, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1327185 · Cited by 8
Shaw, A., Teng, R., Fasina, T., Gonzales, A.-S., Wong, A., Schweitzer, D. R., & Akefe, I. O. (2025) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2025.111299 · Cited by 6
Pushing the limits of LDL cholesterol: Emerging paradigms in cardiovascular risk reduction
Yaghoubi, D., & Sallam, T. (2025) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2025.07.002 · Cited by 6
A safety evaluation of evolocumab
Roth, E. M. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1389892 · Cited by 7
Practical guide for the use of PCSK9 inhibitors in Portugal
Fontes‐Carvalho, R., Silva, P. M., Rodrigues, E., Araújo, F., Gavina, C., Ferreira, J., & Morais, J. (2019) · Revista Portuguesa de Cardiologia (English Edition) · doi:10.1016/j.repce.2019.07.004 · Cited by 7
Eden-Friedman, Y., Steinberg, D. M., Canetti, M., Cohen, I., Segev, S., & Salomon, O. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01529-2 · Cited by 5
Management of Dyslipidemia in Type 2 Diabetes: Recent Advances in Nonstatin Treatment
Sugiyama, K., & Saisho, Y. (2018) · Diseases · doi:10.3390/diseases6020044 · Cited by 6
Inhibiteurs de PCSK9 : quelle place dans la prise en charge actuelle des dyslipidémies ?
Sabouret, P. F., Farnier, M., & Puymirat, É. (2019) · La Presse Médicale · doi:10.1016/j.lpm.2019.01.009 · Cited by 6
Metadata
- Authors
- Giugliano, R. P., Mach, F., Zavitz, K., Kurtz, C., Im, K., Kanevsky, E., Schneider, J., Wang, H., Keech, A., Pedersen, T. R., Sabatine, M. S., Sever, P. S., Robinson, J. G., Honarpour, N., Wasserman, S. M., & Ott, B. R.
- Affiliations
- Oslo University Hospital (NO)
- University of Iowa (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-08-17
- Volume
- 377
- Issue
- 7
- Pages
- 633-643
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2746224452
- Cited by
- 492
- References
- 29
- Citations by year
- 2026: 36 · 2025: 39 · 2024: 35 · 2023: 41 · 2022: 46 · 2021: 63 · 2020: 68 · 2019: 63 · 2018: 75 · 2017: 23
- FWCI
- 64.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- NORA - Norwegian Open Research Archives (submittedVersion, other-oa)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- National Institute for Health and Care Research (NF-SI-0513-10059)
- University of California, Davis
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- evolocumab, PCSK9 inhibitors, cognitive function, executive function, spatial working memory, working memory, episodic memory, psychomotor speed, LDL cholesterol, statin therapy, non-inferiority, cognitive safety, hypercholesterolemia, Alzheimer's disease risk, dementia risk, cognitive decline
- MeSH terms
- Proprotein Convertase 9, PCSK9 Inhibitors, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Anticholesteremic Agents, Cognition, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Cholesterol, LDL, Male, Memory, Middle Aged, Prospective Studies, Psychological Tests, Self-Assessment, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Atherosclerosis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
